Innovative Delivery Platform Ossianix has developed a proprietary blood-brain barrier shuttle technology utilizing shark-derived VNAR antibodies, positioning it as a leader in delivering biologics to brain targets, which could open opportunities for collaborations in neurotherapeutics and CNS drug delivery solutions.

Strategic Partnerships The company has established collaborations with industry leaders like Novo Nordisk and Lundbeck, indicating a strong interest in expanding therapeutics for neurodegeneration, metabolic diseases, and CNS disorders, signaling potential avenues for sales and joint ventures in these areas.

Focus on Neurodegeneration With current programs targeting neurodegeneration, neuro-oncology, ALS, and pain, Ossianix offers opportunities for partnerships in developing and commercializing novel biologics addressing unmet needs in these high-demand neurological markets.

UK and US Presence Ossianix’s strategic locations in both the UK and the US, including research collaborations with UK Science Park Association, provide a strong geographical foundation to access global markets and facilitate international business development efforts.

Growing Innovation Potential As a biotech focused on cutting-edge biologic delivery platforms and early-stage research, Ossianix presents opportunities to engage with innovative biotech and pharmaceutical companies seeking advanced biologic solutions for difficult-to-treat conditions.